- Spinal muscular atrophy is a genetic condition that leads to muscle weakness and atrophy, and nusinersen is a therapy approved for its treatment in both children and adults.
- A clinical case series involving 20 pediatric and 18 adult patients in Kuwait was conducted to evaluate the effectiveness and safety of nusinersen, using various motor function assessments.
- Results showed that about 70% of pediatric and 72% of adult patients experienced significant improvements in motor function, with the therapy being well-tolerated over a period extending beyond four years.
Our understanding of genetic causes behind neurological disorders is still limited, prompting researchers to conduct whole-exome sequencing on 143 families where known disease genes were ruled out.
They discovered 69 new recessive genes linked to these disorders, with detailed descriptions of 33 of them.
The study also noted that in some cases, the observed symptoms did not match the typical presentations of known diseases, but they successfully identified likely causal mutations in over 73% of the cases examined.